Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models

Tiziana Vaisitti, Francesca Arruga, Nicoletta Vitale, Thanh-Trang Lee, Mira Ko, Amy Chadburn, Esteban Braggio, Arianna Di Napoli, Andrea Iannello, John N. Allan, Langdon L. Miller, Brian J. Lannutti, Richard R. Furman, Katti A. Jessen, Silvia Deaglio

Blood (2021) 137 (24): 3365–3377.

https://doi.org/10.1182/blood.2020008404

Published: 2021

Includes: Supplemental data

Journal Articles

VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-136373

Published: 2020

Journal Articles

Targeting ROR1 Using the Antibody Drug Conjugate Vls-101 in Aggressive Mantle Cell Lymphoma

Vivian Changying Jiang, PhD, Yang Liu, PhD, Joseph McIntosh, BS, Alexa A Jordan, BS, Angela Leeming, Zhihong Chen, Katti A. Jessen, PhD, Brian J. Lannutti, PhD, Michael Wang, MD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-137660

Published: 2020

Journal Articles

The ETS Inhibitors Yk-4-279 and TK-216 Interfere with Spib and Synergize with Lenalidomide in Diffuse Large B Cell Lymphoma of the Activated B Cell-like Type (ABC DLBCL)

Elaine Y Chung, PhD, Filippo Spriano, Ivo Kwee, PhD, Sara Napoli, Chiara Tarantelli, PhD, Eugenio Gaudio, PhD, Luciano Cascione, PhD, Andrea Cavalli, Alberto Arribas, PhD, Andrea Rinaldi, Davide Rossi, MD PhD, Emanuele Zucca, MD, Anastasios Stathis, MD, Katti Jessen, PhD, Brian J Lannutti, PhD, Jeffrey Toretsky, MD, Francesco Bertoni, MD

Blood (2017) 130 (Supplement 1): 2810.

https://doi.org/10.1182/blood.V130.Suppl_1.2810.2810

Published: 2017

Journal Articles

TK216, a Novel, Small Molecule Inhibitor of the ETS-Family of Transcription Factors, Displays Anti-Tumor Activity in AML and DLBCL

Katayoun Jessen, PhD, Eric Moseley, PhD, Elaine Yee Lin Chung, PhD, Lauren Otuski, BS, Chiara Tarantelli, PhD, Eugenio Gaudio, PhD, James Breitmeyer, MD PhD, James Freddo, MD, Jeffrey Toretsky, MD, Francesco Bertoni, MD, Brian J Lannutti, PhD

Blood (2016) 128 (22): 4035.

https://doi.org/10.1182/blood.V128.22.4035.4035

Published: 2016

Journal Articles

The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia

Sarah E. M. Herman, PhD, Arnau Montraveta, BS, Carsten U Niemann, MD PhD, Helena Mora-Jensen, PhD, Michael Gulrajani, BS, Fanny Krantz, Bonnie K. Harrington, DVM, Todd Covey, Brian J Lannutti, PhD, Raquel Izumi, PhD, Roger G Ulrich, PhD, John C. Byrd, MD, Adrian Wiestner, MD PhD, Amy J. Johnson, PhD, Jennifer A. Woyach, MD

Blood (2015) 126 (23): 2920.

https://doi.org/10.1182/blood.V126.23.2920.2920

Published: 2015

Journal Articles

ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity

Bonnie K. Harrington, DVM, Michael Gulrajani, BS, Todd Covey, Allard Kaptein, PhD, Bart Van Lith, Raquel Izumi, PhD, Ahmed Hamdy, MBBCh, Roger Glenn Ulrich, PhD, John C Byrd, MD, Brian J Lannutti, PhD, Amy J. Johnson, PhD

Blood (2015) 126 (23): 2908.

https://doi.org/10.1182/blood.V126.23.2908.2908

Published: 2015

Journal Articles

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

Jennifer R. Brown, John C. Byrd, Steven E. Coutre, Don M. Benson, Ian W. Flinn, Nina D. Wagner-Johnston, Stephen E. Spurgeon, Brad S. Kahl, Celeste Bello, Heather K. Webb, Dave M. Johnson, Sissy Peterman, Daniel Li, Thomas M. Jahn, Brian J. Lannutti, Roger G. Ulrich, Albert S. Yu, Langdon L. Miller, Richard R. Furman

Blood (2014) 123 (22): 3390–3397.

https://doi.org/10.1182/blood-2013-11-535047

Published: 2014

Includes: Supplemental data

Journal Articles

PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML

Charles B Goodwin, Xing Jun Li, Raghuveer S. Mali, Gordon Chan, Michelle Kang, Ziyue Liu, Bart Vanhaesebroeck, Benjamin G. Neel, Mignon L. Loh, Brian J. Lannutti, Reuben Kapur, Rebecca J. Chan

Blood (2014) 123 (18): 2838–2842.

https://doi.org/10.1182/blood-2013-10-535104

Published: 2014

Journal Articles

PI3Kδ Inhibitor Idelalisib Inhibits AKT Signaling In Myelofibrosis Patients On Chronic JAK Inhibitor Therapy

Sarah A Meadows, Huong (Marie) Nguyen, M.D., Christophe Queva, PhD, Brian J. Lannutti, PhD, Adam Kashishian, Susie Jun, MD, PhD, Steven E. Coutre, MD, Roger Dansey, MD, Jason Gotlib, MD, MS

Blood (2013) 122 (21): 4065.

https://doi.org/10.1182/blood.V122.21.4065.4065

Published: 2013

Journal Articles

In Vitro Effects of PI3Kδ Inhibitor GS-1101 (Cal-101) in Acute Lymphoblastic Leukemia (ALL)

Nathalie Y Rosin, PhD, Stefan Koehrer, MD, Ekaterina Kim, MS, Susan O'Brien, M.D., William G. Wierda, MD, Ph.D., Deborah A. Thomas, MD, Zeev Estrov, MD, PhD, Hagop M. Kantarjian, MD, Brian J. Lannutti, PhD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 3534.

https://doi.org/10.1182/blood.V120.21.3534.3534

Published: 2012

Journal Articles

Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study

Steven E. Coutre, MD, John P. Leonard, MD, Richard R. Furman, MD, Jacqueline C. Barrientos, MD, Sven de Vos, MD, PhD, Ian W. Flinn, MD, PhD, Marshall T. Schreeder, MD, Nina D. Wagner-Johnston, MD, Jeff Sharman, MD, Thomas E. Boyd, MD, Nathan H Fowler, MD, Leanne M. Holes, Brian J. Lannutti, PhD, Dave M. Johnson, Langdon L Miller, MD, Thomas M. Jahn, MD/PhD

Blood (2012) 120 (21): 191.

https://doi.org/10.1182/blood.V120.21.191.191

Published: 2012

Journal Articles

A Potential Therapeutic Strategy for Chronic Lymphocytic Leukemia by Combining GS-1101, a PI3 kinase Delta (PI3Kδ) Inhibitor and a Novel Highly Selective Spleen Tyrosine Kinase (Syk) Inhibitor, GS-9973

Russell T Burke, Astrid Clarke, Sarah A Meadows, Marc M Loriaux, MD, PhD, Jennifer B Dunlap, MD, Guang Fan, MD, PhD, Patricia Maciejewski, Julie Di Paolo, Brian J. Lannutti, PhD, Brian J. Druker, Stephen E Spurgeon, MD

Blood (2012) 120 (21): 3876.

https://doi.org/10.1182/blood.V120.21.3876.3876

Published: 2012

Journal Articles

The PI3K Inhibitor GS-1101 (CAL-101) Synergistically Potentiates HDAC-Induced Proliferation Inhibition and Apoptosis Through the Activation of JNK in Lymphoma Cells

Juraj Bodo, PhD, Brian T. Hill, MD, PhD, Xiaoxian Zhao, PhD, Craig A. Portell, MD, Brian J. Lannutti, PhD, Eric D. Hsi, MD

Blood (2012) 120 (21): 3714.

https://doi.org/10.1182/blood.V120.21.3714.3714

Published: 2012

Journal Articles

Comprehensive in Vitro and in Vivo Analysis of Phosphatidylinositol-3-Kinase Delta (PI3Kδ) Inhibition Using GS-1101 (CAL-101) in Combination with Mammalian Target of Rapamycin (mTOR) Inhibition Using Temsirolimus or Everolimus in Mantle Cell Lymphoma (MCL)

Paul M. Barr, MD, Francisco J. Hernandez-Ilizaliturri, MD, Thomas Murante, BS, Shannon P. Hilchey, PhD, Derick R Peterson, PhD, Jennifer L. Kelly, PhD, MPH, Dave M. Johnson, Brian J. Lannutti, PhD, Myron S. Czuczman, MD, Jonathan W. Friedberg, MD, Steven H. Bernstein, MD

Blood (2012) 120 (21): 3719.

https://doi.org/10.1182/blood.V120.21.3719.3719

Published: 2012

Journal Articles

Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study

Nathan H Fowler, MD, Sven de Vos, MD, PhD, Marshall T. Schreeder, MD, John P. Leonard, MD, Ian W. Flinn, MD, PhD, Steve Coutre, MD, Nina D. Wagner-Johnston, MD, Jeff Sharman, MD, Ralph V. Boccia, MD, Jacqueline C. Barrientos, MD, Thomas E. Boyd, MD, Leanne M. Holes, Brian J. Lannutti, PhD, David Johnson, Thomas M. Jahn, MD/PhD, Langdon L Miller, MD, Wayne R Godfrey, MD

Blood (2012) 120 (21): 3645.

https://doi.org/10.1182/blood.V120.21.3645.3645

Published: 2012

Journal Articles

Phosphoinositide 3'-Kinase (PI3K) Delta Inhibitor, GS-9820, Enhances Anti-Tumor Efficacy When Combined with Conventional Chemotherapeutic Agents in Primary Samples and Human Tumor Xenograft Model of Multiple Myeloma

Eric Sanchez, Mingjie Li, Cathy Wang, Haiming Chen, MD., Ph.D, Dave M. Johnson, Brian J. Lannutti, PhD, James R. Berenson, MD

Blood (2012) 120 (21): 4017.

https://doi.org/10.1182/blood.V120.21.4017.4017

Published: 2012

Journal Articles

Induction of Early G1-Arrest by CDK4/CDK6 Inhibition Sensitizes Mantle Cell Lymphoma Cells to Selective PI3Kδ Inhibition by GS-1101 Through Enhancing the Magnitude and Duration of p-AKT Inhibition

David Chiron, PhD, Peter Martin, MD, Maurizio Di Liberto, Ph.D., Xiangao Huang, PhD, Scott A Ely, MD, MPH, Brian J. Lannutti, PhD, John P. Leonard, MD, Christopher E. Mason, PhD, Selina Chen-Kiang, PhD

Blood (2012) 120 (21): 791.

https://doi.org/10.1182/blood.V120.21.791.791

Published: 2012

Journal Articles

Therapeutic Utility of PI3Kγ Inhibition in Leukemogenesis and Tumor Cell Survival

Thomas Diacovo, MD, Dosh Whye, Evgeni Efimenko, Jianchung Chen, Valeria Tosello, PhD, Kim De Keersmaecker, PhD, Adam Kashishian, Mary Ann Thompson, MD, PhD, Mireia Castillo, MD, Carlos Cordon-Cardo, MD, PhD, Utpal P. Dave, MD, Adolfo A. Ferrando, MD, PhD, Brian J. Lannutti, PhD, Prem Subramaniam

Blood (2012) 120 (21): 1492.

https://doi.org/10.1182/blood.V120.21.1492.1492

Published: 2012

Journal Articles

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia

Matthew S. Davids, Jing Deng, Adrian Wiestner, Brian J. Lannutti, Lili Wang, Catherine J. Wu, Wyndham H. Wilson, Jennifer R. Brown, Anthony Letai

Blood (2012) 120 (17): 3501–3509.

https://doi.org/10.1182/blood-2012-02-414060

Published: 2012

Includes: Supplemental data

NARROW

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models

VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Targeting ROR1 Using the Antibody Drug Conjugate Vls-101 in Aggressive Mantle Cell Lymphoma

The ETS Inhibitors Yk-4-279 and TK-216 Interfere with Spib and Synergize with Lenalidomide in Diffuse Large B Cell Lymphoma of the Activated B Cell-like Type (ABC DLBCL)

TK216, a Novel, Small Molecule Inhibitor of the ETS-Family of Transcription Factors, Displays Anti-Tumor Activity in AML and DLBCL

The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia

ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML

PI3Kδ Inhibitor Idelalisib Inhibits AKT Signaling In Myelofibrosis Patients On Chronic JAK Inhibitor Therapy

In Vitro Effects of PI3Kδ Inhibitor GS-1101 (Cal-101) in Acute Lymphoblastic Leukemia (ALL)

Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study

A Potential Therapeutic Strategy for Chronic Lymphocytic Leukemia by Combining GS-1101, a PI3 kinase Delta (PI3Kδ) Inhibitor and a Novel Highly Selective Spleen Tyrosine Kinase (Syk) Inhibitor, GS-9973

The PI3K Inhibitor GS-1101 (CAL-101) Synergistically Potentiates HDAC-Induced Proliferation Inhibition and Apoptosis Through the Activation of JNK in Lymphoma Cells

Comprehensive in Vitro and in Vivo Analysis of Phosphatidylinositol-3-Kinase Delta (PI3Kδ) Inhibition Using GS-1101 (CAL-101) in Combination with Mammalian Target of Rapamycin (mTOR) Inhibition Using Temsirolimus or Everolimus in Mantle Cell Lymphoma (MCL)

Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study

Phosphoinositide 3'-Kinase (PI3K) Delta Inhibitor, GS-9820, Enhances Anti-Tumor Efficacy When Combined with Conventional Chemotherapeutic Agents in Primary Samples and Human Tumor Xenograft Model of Multiple Myeloma

Induction of Early G1-Arrest by CDK4/CDK6 Inhibition Sensitizes Mantle Cell Lymphoma Cells to Selective PI3Kδ Inhibition by GS-1101 Through Enhancing the Magnitude and Duration of p-AKT Inhibition

Therapeutic Utility of PI3Kγ Inhibition in Leukemogenesis and Tumor Cell Survival

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only